CRVS

insider transactions

Corvus Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Cluster buy signal: 2 different insiders made open-market purchases in the last 365 days, totalling $333.7K.

Net shares · 365d

+21.8K

28.6K buy · 6.9K sell

Net value · 365d

-$401.4K

$333.7K in · $735.0K out

Sentiment · 365d

Net buying

31% buying · 69% selling

Open-market trades · 365d

28.6K buy · 6.9K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 11, 26

David Scott Moore

Director

$0

15.0K sh

Own New
Buy·P
Jun 11, 26

David Scott Moore

Director

$250.2K

21.7K sh · $11.53

Own New
Grant·A
Jun 11, 26

Linda Grais

Director

$0

15.0K sh

Own New
Grant·A
Jun 11, 26

Peter A. Thompson

Director, 10% Owner

$0

15.0K sh

Own New
Grant·A
Jun 11, 26

Richard Van Den Broek

Director

$0

15.0K sh

Own New
Grant·A
Jun 11, 26

Ian T Clark

Director

$0

15.0K sh

Own New
Grant·A
May 27, 26

Ian T Clark

Director

$0

20.6K sh

Own New
Grant·A
May 27, 26

Ian T Clark

Director

$0

5.1K sh

Own +31%
Sell·S
May 20, 26

Ian T Clark

Director

$735.0K

6.9K sh · $106.90

Own -70%
Buy·P
May 18, 26

Richard A Miller MD KEY

President and CEO

$23.2K

1.9K sh · $12.01

Own +0%
Buy·P
May 18, 26

Richard A Miller MD KEY

President and CEO

$60.2K

5.0K sh · $12.05

Own +0%
Grant·A
Apr 23, 26

Andrew C. Chan

Director

$0

30.0K sh

Own New
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$0

15.0K sh

Own New
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$0

30.0K sh

Own New
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$31.8K

15.0K sh · $2.12

Own +8%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$24.6K

15.0K sh · $1.64

Own +8%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$37.4K

15.0K sh · $2.49

Own +9%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$14.5K

15.0K sh · $0.97

Own +10%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$14.8K

15.0K sh · $0.99

Own +11%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$39.0K

15.0K sh · $2.60

Own +12%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$41.1K

15.0K sh · $2.74

Own +14%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$49.0K

15.0K sh · $3.27

Own +17%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$30.0K

15.0K sh · $2.00

Own +20%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$54.1K

15.0K sh · $3.61

Own +25%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$187.5K

15.0K sh · $12.50

Own +33%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$145.5K

15.0K sh · $9.70

Own +50%
Exercise·M
Jan 28, 26

Peter A. Thompson

Director, 10% Owner

$450.0K

30.0K sh · $15.00

Own New

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 11, 2026	David Scott Moore	Director	Grant A	15.0K	New	—	$0
Jun 11, 2026	David Scott Moore	Director	Buy P	21.7K	New	$11.53	$250.2K
Jun 11, 2026	Linda Grais	Director	Grant A	15.0K	New	—	$0
Jun 11, 2026	Peter A. Thompson	Director, 10% Owner	Grant A	15.0K	New	—	$0
Jun 11, 2026	Richard Van Den Broek	Director	Grant A	15.0K	New	—	$0
Jun 11, 2026	Ian T Clark	Director	Grant A	15.0K	New	—	$0
May 27, 2026	Ian T Clark	Director	Grant A	20.6K	New	—	$0
May 27, 2026	Ian T Clark	Director	Grant A	5.1K	+31%	—	$0
May 20, 2026	Ian T Clark	Director	Sell S	6.9K	-70%	$106.90	$735.0K
May 18, 2026	Richard A Miller MD KEY	President and CEO	Buy P	1.9K	+0%	$12.01	$23.2K
May 18, 2026	Richard A Miller MD KEY	President and CEO	Buy P	5.0K	+0%	$12.05	$60.2K
Apr 23, 2026	Andrew C. Chan	Director	Grant A	30.0K	New	—	$0
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	New	—	$0
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	30.0K	New	—	$0
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+8%	$2.12	$31.8K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+8%	$1.64	$24.6K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+9%	$2.49	$37.4K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+10%	$0.97	$14.5K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+11%	$0.99	$14.8K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+12%	$2.60	$39.0K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+14%	$2.74	$41.1K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+17%	$3.27	$49.0K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+20%	$2.00	$30.0K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+25%	$3.61	$54.1K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+33%	$12.50	$187.5K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	15.0K	+50%	$9.70	$145.5K
Jan 28, 2026	Peter A. Thompson	Director, 10% Owner	Exercise M	30.0K	New	$15.00	$450.0K

About CRVS insider trading

This page tracks insider transactions for Corvus Pharmaceuticals, Inc. (CRVS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.